METHODS OF TREATMENT OF EOSINOPHILIC BRONCHITIS WITH AN ANTI-IL-5 ANTIBODY
The present invention relates generally to the methods for the treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs, Fabs, chimeric and humanized antibodies. More particularly, the present invention relates generally to the treatment of eosinophilic bronchitis with an anti-IL-5 antibody or fragment thereof.
1 . A method for treating eosinophilic bronchitis, comprising administering to a human suffering from eosinophilic bronchitis a composition comprising at least one anti-IL-5 antibody.
2 . The method of claim 1 , wherein said human has steroid-dependent eosinophilic bronchitis.
3 . The method of claim 2 , wherein said steroid is prednisone and/or prednisolone.
4 . The method of claim 1 , wherein said eosinophilic bronchitis is severe.
5 . The method of claim 1 , wherein said at least one anti-IL-5 antibody is to human IL-5.
6 . The method of claim 5 , wherein said at least one anti-IL antibody is neutralizing.
7 . The method of claim 1 , wherein said at least one anti-IL-5 antibody is humanized.
8 . The method of claim 1 , wherein said at least one anti-IL-5 antibody comprises a heavy chain comprising SEQ ID NO: 19.
9 . The method of claim 1 wherein said at least one anti-IL-5 antibody comprises a light chain comprising SEQ ID NO: 21.
10 . The method of claim 1 wherein said human is suffering from at least one additional disorder associated with excess eosinophil production selected from the group consisting of atopic asthma, atopic dermatitis, allergic rhinitis, non-allergic rhinitis, asthma, severe asthma, chronic cosinophilic pneumonia, allergic bronchopulmonary aspergillosis, coeliac disease, Churg-Strauss syndrome, eosinophilic myalgia syndrome, hypereosinophilic syndrome, oedematous reactions including episodic angiodema, helminth infections, eosinophilia associated with a parasitic infection and/or the treatment of parasitic infection, onchocercal dermatitis eosinophilic oesophagitis, eosinophilic gastritis, eosinophilic gastroenteritis, eosinophilic enteritis, eosinophilic colitis, nasal micropolyposis, nasal polyposis, aspirin intolerance asthma, obstructive sleep apnoe, chronic asthma, Crohn's disease, scleroderma and endomyocardial fibrosis.
11 . The method of claim 1 , wherein said composition comprising at least one anti-IL-5 antibody is administered intravenously.
12 . The method of claim 11 , wherein said composition comprising at least one anti-IL-5 antibody is administered at a dose of 750 mg.
13 . The method of claim 11 , wherein said intravenous dose is administered intravenously over 30 minutes.
14 . The method of claim 2 , wherein said human is receiving prednisone for said steroid-dependent eosinophilic bronchitis and said prednisone is reduced by at least about 90% in said human suffering from steroid-dependent eosinophilic bronchitis after treatment with said composition comprising at least one anti-IL-5 antibody.
15 . The method of claim 2 , wherein the human suffering from steroid-dependent eosinophilic bronchitis experiences a statistically significant reduction in exacerbations of eosinophilic bronchitis after receiving at least one doses of said composition comprising at least one anti-IL-5 antibody.
16 . The method of claim 1 , wherein eosinophil level in said human are reduced to within normal limits after at least one dose of said composition comprising at leas one anti-IL-5 antibody.
17 . The method of claim 16 , wherein said eosinophil level remains within normal limits for at least 8 weeks after the last dose of said composition comprising anti-IL-5 antibody.
18 . The method of claim 1 , wherein said composition comprising at least one anti-IL-5 antibody comprises a first anti-IL-5 antibody and a second anti-IL-5 antibody.
19 . The method of claim 1 , wherein said composition comprising at least one anti-IL-5 antibody is co-administered with a steroid.
20 . The method of claim 2 , wherein said composition comprising at least one anti-IL-5 antibody statistically significantly reduces the amount of steroid required by a patient to control exacerbations of eosinophilic bronchitis compared with placebo.
21 . The method of claim 16 , wherein said eosinophil level is reduced in said human in blood and/or sputum.
22 . The method of claim 1 , wherein the patient also suffers from asthma.
23 . The method of claim 22 , wherein the asthma is severe.